Brain-derived neurotrophic factor increases inhibitory synapses, revealed in solitary neurons cultured from rat visual cortex
Nausea is the single most common complaint, affecting a significant percentage of users especially during dose escalation
S., Rose, L., Hansen, T., Zacho, J., Bain, S
NNC0090-2746 (RG7697) is a compound that has been tested in multiple preclinical and clinical studies as a dual GIPR/GLP-1R agonist [58,59,60]
Many participants lost double-digit percentages of weight, which is significant for an oral treatment
If retatrutide's greater efficacy in weight and metabolic parameters translates to cardiovascular outcome data of comparable or superior magnitude, the case for its use as a longevity intervention, not merely an obesity treatment, will be scientifically compelling